GPX1 and neoplasm: In 2017, Wang C et al. conducted a comprehensive meta-analysis including 60 case-control studies and 52 published articles to reveal that GPX1 Pro198Leu polymorphism was only positively associated with the development and progression of bladder, head/neck, and brain cancers among all tumor types [34].